ParagonCare Turns Integration Into 16.5% EBITDA Growth
ParagonCare says it achieved its FY26 guidance and lifted underlying EBITDA 16.5% to $97.2 million, despite a statutory earnings hit from the Infinity Pharmacy Group bad debt. The healthcare distributor is now turning to Asian expansion, operational efficiency and an active share buyback in FY27.
- Underlying EBITDA rose 16.5% to $97.2 million
- Revenue fell 13.6% to $3.7 billion
- Six acquisitions completed across Australia, New Zealand and Asia
- No FY26 dividend after the Infinity bad debt
- On-market share buyback is running daily
Add us as a preferred source on Google
Underlying EBITDA rises as revenue declines
Paragon Care Limited (ASX:PGC) has completed its three-business, two-year integration program with underlying EBITDA up 16.5% to $97.2 million, even as revenue fell 13.6% to $3.7 billion in FY26. Underlying NPAT rose 2.1% to $26.0 million, while underlying net debt increased 1.8% to $23.7 million, equivalent to 2.5 times underlying EBITDA.
Chair Peter Lacaze said the company achieved its guidance targets for sales, EBITDA and net debt. The result was helped by the completion of six acquisitions, the alignment of Australian operations onto the JDE enterprise resource planning platform, and the commissioning of a new automated Brisbane warehouse.
The headline earnings picture remains more complicated. Statutory earnings were affected by non-recurring items, chiefly the Infinity Pharmacy Group bad debt. ParagonCare previously reported a $38 million credit loss provision linked to the exposure, while recovery from the administration process remains a factor in the eventual cash outcome. The company paid no dividend for FY26 and said the Board would review dividend policy at its half-year results.
Buyback continues after September launch
ParagonCare is buying shares on market daily under the two-part buyback program announced in September. The program was designed to give shareholders options and use prevailing equity market conditions, although the AGM materials do not disclose the number of shares acquired to date.
The initiative follows the company’s September share buyback, which allowed for an on-market repurchase of up to 82.8 million shares and a separate employee share trust facility. The latest presentation confirms that the program is proceeding as expected, but does not provide a revised maximum cost or completion timetable.
Six acquisitions extend the Asian platform
Expansion remains central to ParagonCare’s FY27 plan. The company completed acquisitions including Haju Medical in Indonesia, Somnotec in Southeast Asia, Pacific Medical in Hong Kong and Macau, and Fisher Biotec, AHP and Presidental in Australia. Management said the transactions were selected to fill geographic, product or service gaps.
Haju Medical adds more than 4,000 customers and a portfolio of more than 40 products from 20 brands in Indonesia’s aesthetics market, while Somnotec operates across Singapore, Malaysia, Indonesia and the Philippines. Pacific Medical is expected to expand into Australia in FY27 through existing and new supplier relationships.
FY27 priorities shift to execution and cash
For the new financial year, ParagonCare plans to continue expanding in Asia, grow its aesthetics operations, pursue strategic acquisitions and develop its product and service offering. It also intends to review its supply chain network, invest in technology, use its Asian offices to support administration functions and focus on working capital improvement.
The first-quarter presentation showed 94% of revenue coming from Australia and New Zealand and 6% from Asia. That mix puts the company’s expansion ambitions in perspective: the acquisitions are broadening the platform, but the financial contribution from Asia is still relatively small in the disclosed quarter. The company also said it had commenced a five-year Australian Defence Force supply contract, without providing contract revenue or earnings details.
Bottom Line?
The integration phase is complete, but FY27 will test whether acquisitions, Asian expansion and working-capital improvements can convert underlying earnings growth into stronger cash generation and restore dividend capacity.
Questions in the middle?
- How much of the FY27 result will come from the six recently completed acquisitions?
- What cash recovery, if any, will ParagonCare ultimately receive from the Infinity administration?
- When will the buyback and acquisition program begin to translate into lower leverage or renewed dividends?
Sources
1-
2026 Annual General Meeting Chair Address & Presentation (opens in a new tab)Official market announcement. Paragon Care Limited · 18 Nov 2026 · paragoncare.com.au